PWSA Blog

Boss Building our Social Skills

Joint Announcement: FPWR Partners with PWSA | USA to Provide BOSS Social Skills Groups for Teens and Adults with PWS

PWSA | USA (Prader-Willi Syndrome Association | USA) and FPWR (Foundation for Prader-Willi Research) are thrilled to announce a groundbreaking collaboration to address the social challenges faced by individuals with Prader-Willi syndrome (PWS). FPWR funding has facilitated the development of the Building Our Social Skills (BOSS) curriculum, a highly effective social skills intervention program created...

Healthy Holiday Recipes

Silly Apple Monsters Ingredients: 3 green apples 3 tablespoons creamy peanut butter 2 ounces of sliced cheese (cheddar or colby jack both work) 2 tablespoons of pumpkin or sunflower seeds A package of candy eyes Instructions: Quarter the green apples and slice off the core and seeds. Carefully cut out a v-shape into the center...

Celebrate Thanksgiving Safely

by Katherine Crawford, former PWCF Family Support Coordinator Updated by Lisa Graziano, M.A., PWCF Education and Training Consultant Holidays are a time for gathering, connecting, and celebrating – but are also typically centered on food, which often places enormous stressors on families of a child or adult with PWS. We hope the following tips make...

Soleno Therapeutics Reports Positive Results from DCCR Study C602 for Prader-Willi Syndrome

Soleno Therapeutics, Inc. has revealed positive outcomes from the randomized withdrawal phase of Study C602, an extended treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for Prader-Willi syndrome (PWS). The results, which showed a significant improvement in hyperphagia-related behaviors in the DCCR group compared to the placebo group, support Soleno's plan to submit a New...

Empowering Families Dealing with Prader-Willi Syndrome Through Food Security

Transformative Tales: Empowering Families Dealing with Prader-Willi Syndrome Through Food Security

Contributed by Christopher Rich, Utah PWS Association Living with Prader-Willi Syndrome (PWS) presents unique challenges, particularly in managing food-related behaviors. The experiences of families dealing with PWS takes on an extra layer of complexity, because of the significance of food control and security devices in their lives. In the below excerpts, we dive into those...

Neuren Pharmaceuticals is Happy to Announce the First Site Participating in Their Phase II, Open Label, PWS Study (Neu-2591-PWS-001) is Now Open for Screening!

Important information regarding this exciting milestone: Rare Disease Research (RDR), located in Atlanta, GA, is now welcoming children with PWS and their families to their clinicfor screening into this trial. The duration of active treatment in this study is 13 weeks. In a preclinical study in animals, physiological and behavioral symptoms were normalized within six...

Harmony Biosciences Issues Statement Regarding Confidence in Pitolisant Drug

Harmony Biosciences has reaffirmed its confidence in the strength of WAKIX® (Pitolisant) patents, after receiving a positive ruling from the U.S. Patent and Trademark Office (USPTO) rejecting the request for reexamination. WAKIX® is used to treat excessive daytime sleepiness (EDS) or cataplexy in adults with Narcolepsy. Read Harmony Biosciences' community-facing statement below: We are pleased...

2023 Moms’ Retreat Attendees Selected!

Thank you to everyone who submitted an application to attend PWSA | USA's first-ever Moms' Retreat, October 12-15, 2023, in Palm Spring, California! On Friday, August 18, 2023, 30 applicants were randomly selected to attend the event. Our staff will be reaching out to these individuals to provide additional details and collect information. Below you...

Help Rare Disease Research Efforts by Sharing Blood, Urine Samples with PWS-COMBINEDBrain Biorepository

We are sharing details on behalf of The Foundation for Prader-Willi Research (FPWR) to spread the word about an upcoming and important PWS research opportunity. FPWR is collaborating with COMBINEDBrain to establish a biorepository dedicated to blood and urine samples. This initiative aims to expedite the development of treatments for individuals with Prader-Willi Syndrome, as...

Aardvark Therapeutics Announces FDA Pediatric Disease Designation for PWS, Expansion of Phase 2 Clinical Trial

Aardvark Therapeutics recently announced the drug company has received Pediatric Disease Designation for PWS from the U.S. Food and Drug Administration (FDA), and will expand its Phase 2 clinical trial of oral ARD-101 in young adults with PWS. According to Aardvark Therapeutics, this FDA designation means the company is eligible for a Rare Pediatric Disease...

How Utah is Enhancing Food Security for Prader-Willi Syndrome Individuals: 2023 PWS National Convention

Contributed by Christopher Rich, Utah PWS Association Among the exhibitors at this year's PWSA | USA National Convention was the Utah PWS Association, which focused on food security and its role in managing PWS symptoms. The exhibition booth showcased practical strategies and innovative solutions to create a controlled environment, emphasizing the importance of food security...

Share Your School Lunch Tips

On Friday, July 28, 2023, PWSA | USA's Special Edition Pulse will focus on back-to-school and offer helpful tips from our Family Support team as well as how to best utilize our School Success resources. We also want to hear from YOU, our PWS community, on what has worked for you / your loved one...

Prader-Willi Syndrome Association | USA Announces the Resignation of CEO Paige Rivard and Appointment of Interim CEO Stacy Ward

July 12, 2023 – The Prader-Willi Syndrome Association | USA (PWSA | USA) announces the resignation of its CEO, Paige Rivard, MBA. Paige held the CEO position for the past three years and has led many efforts to advance awareness, research opportunities, and provide support for families in the Prader-Willi syndrome (PWS) community. The association...

Acadia Pharmaceuticals Announces Next Phase for ACP-101 (Intranasal Carbetocin) After Meeting with FDA

This week, Acadia Pharmaceuticals made the announcement the drug company plans to begin Phase 3 of ACP-101, intranasal carbetocin, later this year after a recent meeting with the U.S. Food and Drug Administration (FDA). ACP-101 is currently being studied to treat hyperphagia in Prader-Willi syndrome. Learn more about this announcement by reading Acadia Pharmaceuticals’ full...

Scroll to top